All In MedTech

Device Trial Radar · NCT02987387

COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction

New Enrollment SAPIEN XT Post-Approval Study

Last checked: Nov 20, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

57

Actual

Start

Jul 17, 2017

Primary completion

Aug 9, 2021

Study completion Sep 30, 2025

Sponsor

Lead sponsor
Edwards LifesciencesPublic (EW)
Sponsor type
Industry
First posted
Dec 8, 2016

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will confirm the safety and effectiveness of the Edwards Lifesciences SAPIEN XT Transcatheter Heart Valve (THV) System in patients with a dysfunctional right ventricular outflow tract (RVOT) conduit with a clinical indication for intervention in a post-market setting.

Conditions

  • Pulmonary Valve Insufficiency
  • Pulmonary Valve Stenosis
  • Heart Defects, Congenital
  • Congenital Abnormalities
  • Cardiovascular Diseases
  • Heart Diseases

Interventions

  • SAPIEN XT THVDevice

    SAPIEN XT THV will be implanted in the pulmonic position.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Freedom from device- or procedure-related death or reinterventionTime frame: 1 year

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • Children's Hospital Colorado

    Aurora, Colorado

  • Children's National Medical Center

    Washington D.C., District of Columbia

9 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.